Laurie Barclay, MD
NEW YORK (MedscapeWire) Apr 29 Different interferon regimens vary in their ability to prevent relapses and disease progression in multiple sclerosis (MS), according to the results of a prospective, randomized trial published in the April 27 issue of The Lancet.
"The 3 interferon beta preparations approved for treatment of relapsing-remitting MS differ in dose and frequency of administration," write Luca Durelli and colleagues from Turin University Medical School in Italy. "High-dose interferon beta-1b given every other day is more effective in treating multiple sclerosis (MS) than interferon beta-1a given once a week."
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!